Sugi Predict

Sugi Predict / Compounds / SCHEMBL360739

SCHEMBL360739

SCHEMBL360739

CC(C)(C)OC(=O)NC1CCC(F)(F)CC1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.50
▸ CTSK P43235 2/20 0.47
▸ EPHX2 P34913 2/20 0.46
▸ GAA P10253 2/20 0.45
▸ EPHX1 P07099 1/20 0.44
▸ KDM1A O60341 1/20 0.44
▸ MAOB P27338 1/20 0.44
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ NFKB1 P19838 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41
▸ CYP2C9 P11712 1/20 0.39
▸ HSD11B1 P28845 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ DRD2 P14416 2/20 0.39
▸ KCNA3 P22001 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1951353 0.90 BTK (0.48) BTKCTSKEPHX2GAAEPHX1
SCHEMBL2544844 0.90 BTK (0.48) BTKCTSKEPHX2GAAEPHX1
SCHEMBL23012500 0.86 GAA (0.54) BTKCTSKEPHX2GAAEPHX1
SCHEMBL12544593 0.85 CTSK (0.48) BTKCTSKEPHX2GAAEPHX1
SCHEMBL21724900 0.85 BTK (0.50) BTKCTSKEPHX2GAAEPHX1
SCHEMBL21774792 0.85 BTK (0.50) BTKCTSKEPHX2GAAEPHX1
SCHEMBL12354755 0.85 BTK (0.47) BTKCTSKEPHX2GAAEPHX1
SCHEMBL13035982 0.84 BTK (0.51) BTKCTSKEPHX2GAAEPHX1
SCHEMBL18929028 0.84 BTK (0.51) BTKCTSKEPHX2GAAEPHX1
SCHEMBL20656858 0.84 BTK (0.46) BTKCTSKEPHX2GAAEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3985001-B1 PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER SERVIER LAB (FR) 2026-04-29 — — EP disclosed
WO-2025224168-A1 ARYL SULFONE AND SULFANONE DERIVATIVES AS OREXIN RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2025-10-30 — — WO disclosed
US-20240059733-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC (US) 2024-02-22 — — US disclosed
WO-2023178181-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-09-21 — — WO disclosed
EP-4245756-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF Gilead Sciences, Inc. (US) 2023-09-20 — — EP disclosed
US-11667673-B2 Therapeutically active compounds and their methods of use SERVIER PHARMACEUTICALS LLC (US) 2023-06-06 — — US disclosed
US-11667673-B2 Therapeutically active compounds and their methods of use SERVIER PHARMACEUTICALS LLC (US) 2023-06-06 — — US disclosed
US-11667673-B2 Therapeutically active compounds and their methods of use SERVIER PHARMACEUTICALS LLC (US) 2023-06-06 — — US disclosed
CN-115850156-A Method for purifying difluoride compound 上海泰坦科技股份有限公司 2023-03-28 — — CN disclosed
EP-3985001-A1 PHARMACEUTICAL COMPOSITION USEFUL IN INHIBITING IDH1 Les Laboratoires Servier SAS (FR) 2022-04-20 — — EP disclosed
EP-1723128-A1 HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2006-11-22 — — EP disclosed
US-20060235019-A1 Substituted quinazolinone compounds CHIRON CORPORATION 2006-10-19 — — US disclosed
US-7034033-B2 Substituted quinazolinone compounds CHIRON CORPORATION (US) 2006-04-25 — — US disclosed
US-20060030573-A1 Substituted quinazolinone compounds BOYCE RUSTUM S 2006-02-09 — — US disclosed
US-20050192297-A1 Quinazolinone compounds with reduced bioaccumulation CHIRON CORPORATION GLAXOSMITHKLINE 2005-09-01 — — US disclosed
WO-2005066145-A1 HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2005-07-21 — — WO disclosed
WO-2005058892-A1 PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2005-06-30 — — WO disclosed
US-20050059662-A1 Substituted quinazolinone compounds CHIRON CORPORATION 2005-03-17 — — US disclosed
WO-2004056823-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-07-08 — — WO disclosed
US-20040019049-A1 Substituted quinazolinone compounds CHIRON CORPORATION 2004-01-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235019-A1 Substituted quinazolinone compounds MC4R, MC2R, MC5R BTK 1705/4885CTSK 2475/4885EPHX2 4397/4885
US-20050059662-A1 Substituted quinazolinone compounds MC4R, MC2R, MC3R BTK 1216/4885CTSK 2020/4885EPHX2 4541/4885
US-20240059733-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE IDH1, IDH3B, IDH3A BTK 1909/4885CTSK 1181/4885EPHX2 1564/4885
US-20040019049-A1 Substituted quinazolinone compounds MC4R, MC2R, MC3R BTK 1504/4885CTSK 1926/4885EPHX2 4537/4885
US-20060030573-A1 Substituted quinazolinone compounds MC4R, MC2R, MC3R BTK 1707/4885CTSK 1994/4885EPHX2 4521/4885
US-11667673-B2 Therapeutically active compounds and their methods of use IDH1, IDH3B, IDH3A BTK 1909/4885CTSK 1181/4885EPHX2 1564/4885
US-20050192297-A1 Quinazolinone compounds with reduced bioaccumulation MC4R, MC2R, MC3R BTK 2505/4885CTSK 2404/4885EPHX2 3770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.